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Abstract
Patients suffering from liver cirrhosis (LC) frequently 
require non-hepatic abdominal surgery, even before 
liver transplantation. LC is an important risk factor itself 
for surgery, due to the higher than average associated 
morbidity and mortality. This high surgical risk occurs 
because of the pathophysiology of liver disease itself 
and to the presence of contributing factors, such 
as coagulopathy, poor nutritional status, adaptive 
immune dysfunction, cirrhotic cardiomyopathy, and 
renal and pulmonary dysfunction, which all lead to 
poor outcomes. Careful evaluation of these factors 
and the degree of liver disease can help to reduce the 
development of complications both during and after 
abdominal surgery. In the emergency setting, with the 
presence of decompensated LC, alcoholic hepatitis, 
severe/advanced LC, and significant extrahepatic 
organ dysfunction conservative management is 
preferred. A multidisciplinary, individualized, and 
specia l ized approach can improve outcomes; 
preoperative optimization after risk stratification and 
careful management are mandatory before surgery. 
Laparoscopic techniques can also improve outcomes. 
We review the impact of LC on surgical outcome 
in non-hepatic abdominal surgeries required in this 
cirrhotic population before, during, and after surgery. 
Key words: Liver cirrhosis; Outcomes; Coagulopathy; 
Nutritional status; Abdominal surgery; Adaptive 
levels of expertise of the surgeons, anesthetists, 
and intensive care unit (ICU) staff. Liver function is 
usually assessed by the Child-Turcott-Pugh (CTP) and 
Model for End-Stage Liver Disease (MELD) scores[11]. 
Early studies found 30 d mortality rates after surgery 
were 10% in CTP-A, 30% in CTP-B, and 76%-82% 
in CTP-C, figures that have not significantly changed 
in more recent assessments[12,13]. Despite the poor 
results, advances in the medical management of LC 
and life expectancy have increased the eligibility of 
these patients for abdominal surgery[14]. To be able 
to give definitive recommendations and indications 
for non-hepatic abdominal surgery in the cirrhotic 
population, it is important to identify the patients most 
likely to benefit from it. There is also a need to assess 
contemporary surgical techniques and the various 
scoring systems currently in use. 
This review summarizes the outcomes of patients 
with LC undergoing non-hepatic abdominal surgery. 
Indexed articles in Medline of series of patients with LC 
who underwent non-hepatic abdominal surgery between 
1950 and March 2014 were reviewed using the OVID 
interface. We aimed to select manuscripts addressing 
outcome based on the degree of LC assessed with 
MELD and/or CTP scores. Articles addressing the 
pathophysiology of cirrhotic patients and the clinical 
implications in non-hepatic abdominal surgery were 
selected based on their importance, their date of 
publication, and the citations of the manuscripts. As for 
articles describing the different types of surgery in LC 
patients, the most recent publications were selected in 
order to preserve comparability between contemporary 
surgical techniques. For these reasons, the present 
review does not follow the Preferred Reporting Items 




CONSIDERATIONS OF LC BEFORE 
SURGERY 
The estimation of liver functional reserve and the 
identification of coexisting pathophysiological disorders, 
such as coagulopathy, malnutrition, cardiomyopathy, 
renal dysfunction, respiratory dysfunction, ascites, 
and hyponatremia, are key issues in the preoperative 
evaluation of LC patients scheduled for non-hepatic 
abdominal surgery. Despite the lack of evidence-
based guidelines for the management of these 
patients, clinical and surgical teams are acquiring 
experience with LC patients undergoing non-hepatic 
abdominal surgery, and the body of knowledge of the 
pathophysiology of LC in the literature is increasing. 
Therefore, some general recommendations for the 
care of these patients are in order[15].
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Core tip: The prevalence of chronic liver disease is 
increasing. Patients with liver cirrhosis may be more 
likely to need non-hepatic abdominal surgery than 
the non-cirrhotic population. The rising incidence of 
non-alcoholic fatty liver disease and non-alcoholic 
steatohepatitis may increase the prevalence of cirrhotic 
patients within the abdominal surgery population. The 
pathophysiological characteristics of the condition raise 
the surgical risk and the likelihood of poor prognosis. 
A review of the assessment and outcomes for non-
hepatic abdominal procedures in these patients is 
essential since most current recommendations are 
based on observational studies. 
Lopez-Delgado JC, Ballus J, Esteve F, Betancur-Zambrano NL, 
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Mortality and morbidity rates are high in patients with 
liver cirrhosis (LC) requiring non-hepatic abdominal 
surgical procedures[1,2]. Despite the lack of reliable 
epidemiological data, the incidence of LC is expected to 
increase due to alcohol consumption and the potential 
high rates of hepatitis C virus (HCV) and hepatitis B 
virus (HBV) in coming years in European countries[3,4]. 
In addition, the obesity epidemic in Western countries, 
which is associated with metabolic syndrome, is 
expected to generate a large cohort of patients with 
non-alcoholic steatohepatitis (NASH) and non-alcoholic 
fatty liver disease (NAFLD) that may potentially change 
the etiological pattern of LC[5,6].
LC patients may require surgery for abdominal 
wall hernia, gallstones[7], peptic ulcer disease, biliary, 
small bowel, colo-rectal, and pancreatic diseases as 
well as liver procedures, such as transplantation. 
Surgery represents an additional source of stress 
for compromised liver function, and perioperative 
complications frequently appear in spite of significant 
advances in surgical and intensive care management[8]. 
Preoperative risk stratification is difficult due to the 
limited accuracy of the tools available to assess LC, 
and, in some cases, due to the absence of diagnosis. 
The mortality and morbidity risks are associated with 
the severity of the underlying LC[9,10]. This is one of the 
factors that explains the wide variation in outcomes 
recorded by different studies, in addition to patient 
characteristics, the surgical approach used, and the 
Liver function
The occurrence of portal hypertension (PHT) in LC 
leads to variceal bleeding, ascites, spontaneous 
bacterial peritonitis (SBP), and hepatic encephalopathy. 
Patients with LC are at a higher risk of liver-related 
complications during surgery due to inappropriate 
response to surgical stress. Mortality is higher in non-
hepatic abdominal surgery in the presence of PHT, 
which is also an indicator of illness progression[10,15]. 
The presence of high intraoperative PHT is associated 
with postoperative mortality due to rebleeding[16]. 
Preoperative evaluation of liver function by a physician 
experienced in managing liver disease in patients with 
confirmed or suspected LC is needed in order to stage 
the severity[17]. In clinical practice, severity should be 
assessed by means of both CTP and MELD scores, 
although MELD is more objective[18]. These scores 
should be assessed throughout the patient’s admission 
because rapid deterioration indicates that surgery may 
not be safe. The value of indocyanine green plasma 
disappearance rate has been demonstrated in patients 
with LC undergoing cardiac surgery[19,20] and partial 
hepatectomy[21], and it may be useful for assessing 
liver functional reserve in this scenario. 
As a general rule, surgery is safe in CTP A patients 
without PHT and MELD < 10, but its pros and cons 
should be carefully considered in patients with severe 
LC[22,23]. Surgery should be avoided if possible in the 
setting of acute viral hepatitis, alcoholic hepatitis, acute 
liver failure, acute renal failure, severe coagulopathy, 
hypoxemia, and/or cardiomyopathy[14]. 
Regarding the etiology of LC, certain specific 
considerations need to be addressed before surgery. 
Due to the stress that surgery represents in patients 
with autoimmune hepatitis who are receiving or have 
recently received steroids, increasing the dose is a 
possible alternative. D-Penicillamine, the chelating 
agent used to treat Wilson disease, interferes with 
wound healing and should be reduced 2 wk before 
surgery and until the wound has healed completely. 
Alcohol consumption must be discontinued, especially 
in patients with a history of alcohol abuse, because 
of its associations with the risk of hepatotoxicity from 
drugs such as paracetamol, poor wound healing, 
bleeding, delirium, infections, and alcoholic hepatitis 
(the last of these being a clear contraindication for 
elective surgery in those patients)[24-26]. In addition, 
alcohol abstinence is very difficult, and the majority of 
patients have superimposed alcoholic hepatitis[26].
Coagulopathy
Coagulopathy is the major concern for surgeons, be-
cause both pro- and anti-coagulants present reductions 
in LC. Thrombocytopenia due to poor nutritional status, 
hypersplenism and/or bleeding from varices may 
exacerbate bleeding problems[27,28]. Myelosuppression 
due to hepatitis C, folate deficiency, and ethanol toxicity 
can also aggravate thrombopoietin deficiency[27]. How-
ever, primary homeostasis may not be defective in LC, 
and a low platelet count, if not severe, should not be 
automatically considered as an index of an increased 
risk of bleeding[29]. Thrombocytopenia of < 50000/µL for 
moderate risk and 100000/µL for high risk procedures 
must be corrected by platelet transfusion prior to 
surgery[30]. Infections, renal failure, malabsorption, 
and/or malnutrition can adversely affect coagulation in 
decompensated LC. 
Conventional coagulation tests measure only part of 
the process of thrombin generation. The prothrombin 
time-derived international normalized ratio (PT-INR) 
is universally used to assess bleeding risk and 
prognosis in MELD score and to guide treatment of 
coagulation disturbances in clinical practice; however, 
it only measures the activity of procoagulants. Throm-
boelastography (TEG) provides a better assessment 
of the degree of coagulopathy and offers information 
allowing immediate transfusion therapy. It is useful 
before and during surgery for guiding transfusion 
therapy[31]. Serum fibrinogen, a key factor in fibrin 
clot formation, and protein C deficiency may also 
determine the risk of bleeding in LC[32].
Coagulopathy is one of the factors of LC that can 
be modified preoperatively with intravenous vitamin 
K replenishment and cryoprecipitate transfusions in 
order to maintain a serum fibrinogen level < 100 
mg/dL. Preoperative administration of fresh-frozen 
plasma to correct the INR should be avoided due to its 
ineffectiveness and its association with volume overload, 
exacerbation of PHT, risk of infections, and transfusion-
related acute lung injury[33,34]. Administration of 
desmopressin and tranexamic acid should be considered 
when platelet dysfunction and hyperfibrinolytic state 
are suspected[35]. This may help survival after surgery 
and convert CTP C patients into CTP B by improving the 
coagulopathy[36]. 
The lack of improvement in PT-INR with the ad-
ministration of vitamin K may reflect a poor hepatic 
reserve and outcome. In addition, plasma hemoglobin 
levels lower than 10 g/dL and higher intraoperative 
transfusion needs are independent prognostic factors 
for mortality in these patients[1,18]. These findings 
are linked with a major deterioration of coagulation 
and the association of perioperative blood product 
transfusion with the triggering of the inflammatory 
response[37]. 
Immune dysfunction and nutritional status
Infections are an important cause of death during the 
postoperative period due to an innate and adaptive 
immune dysfunction in LC, which is associated with 
the development of liver dysfunction and an enhanced 
susceptibility to acute inflammatory processes[38,39]. This 
is also linked with nutritional status: between 50% and 
90% of LC patients lack sufficient nutritional reserve 
and have a poor metabolic state, with inadequate 
inflammatory and immune responses to surgery[40,41]. 
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portopulmonary hypertension, and hepatic hydrotho-
rax are typical pulmonary complications. The end-
expiratory lung volume may fall, leading to impairment 
in the mechanics of the respiratory system, lung, and 
chest wall as well as gas-exchange. Thus, initial use of 
moderate Positive End Expiratory Pressure is advisable 
to improve oxygenation and compliance without 
causing adverse effects in the respiratory function[57-59].
Hemodynamic changes, such as systemic vaso-
dilatation and volume retention in the splanchnic bed 
secondary to PHT, reduce preload and the associated 
retention of water and sodium in order to compen-
sate for the low effective circulatory volume. These 
mechanisms explain the development of ascites and 
the impairment of the kidneys in the elimination of 
solute-free water. Ultimately, this also explains the 
development of hyponatremia, which is associated 
with increased morbidity and mortality in patients with 
LC[60]. Sodium < 130 mmol/L in non-hepatic abdominal 
surgery and ascites in general surgery are markers of 
poor prognosis in LC patients[1,8,56]. 
Preoperative portal decompression by transjugular 
intrahepatic portosystemic shunt (TIPS) seems to be 
a safe procedure for reducing the risk of bleeding in 
the presence of varices and the risk of ascites even 
in decompensated LC. Although there is not enough 
evidence to support its routine use before non-
hepatic surgery, it could be considered in patients with 
significant ascites, extensive abdominal varices, or 
both. Reducing portal pressure seems to be helpful in 
decreasing bleeding during surgery[61-63]. 
If possible, these complications need to be screened 
in candidates for surgery, especially in those with a 
medical history consistent with LC-related complications, 
and then medically optimized prior to surgery. Despite 
their implications for the perioperative course of LC 
patients undergoing any type of surgery, they have not 
been adequately addressed in non-hepatic abdominal 
surgery, especially when compared with other major 
surgeries, such as cardiac surgery[2]. In Table 1 
we summarize recommendations for preoperative 
evaluation in patients with LC scheduled for non-hepatic 
abdominal surgery.
INTRAOPERATIVE MANAGEMENT
Patient management during surgery is crucial for 
outcomes in LC. A team-based approach involving 
hepatologists, surgeons, and anesthetists with 
experience in treating LC patients is required, ideally at 
a specialist center[1,8,9]. 
Anesthesiology 
Intraoperative management depends more on the 
anesthesiologist than on the surgeon, because the use 
of anesthesia tends to cause hepatic decompensation 
in patients with LC[64]. Fluid management can be 
difficult since crystalloids (e.g., Hartmann’s solution or 
Malnutrition in patients undergoing abdominal surgery 
is associated with a greater risk of postoperative 
complications and longer hospitalization[42]. Although 
the evidence is controversial, preoperative nutrition 
support may play an important role in preventing 
complications[43]. Nutritional disorders are more 
severe with alcoholic cirrhosis than with non-alcoholic 
cirrhosis, which can explain the poorer prognosis of 
this subgroup of patients when undergoing surgery[44]. 
A combination of transferrin, prealbumin, and albumin 
seems an adequate approach for nutritional evaluation 
in LC[45]. Indeed, hypoalbuminemia has been associated 
with poor outcome in abdominal and colon cancer 
interventions in patients with advanced LC[8,46].
Cardiovascular and renal dysfunction
Preoperative evaluation of cardiovascular dysfunction 
in LC is crucial. Cardiovascular diseases are a common 
cause of mortality in LC because of the severity of liver 
injury, and inflammation is strongly associated with an 
increased cardiovascular risk and an atherogenic lipid 
profile[47]. This is especially relevant in NASH/NAFLD 
chronic liver disease because the etiological risk 
factors are the same for both LC and cardiovascular 
disease, even taking into account the expected rise 
in the incidence of NASH/NAFLD worldwide[48]. A 
hyperdynamic circulatory state with increased cardiac 
output in response to splanchnic arterial vasodilatation 
is an inherent characteristic of LC, leading to heart 
failure with the progression of liver disease. Cirrhotic 
cardiomyopathy develops a variety of progressive 
clinical manifestations and is characterized by diastolic 
dysfunction and impaired inotropic and chronotropic 
competence, leading to a suboptimal ventricular 
contractile response during stressful conditions[49,50]. 
The dynamic assessment of preoperative cardiac 
function with dobutamine stress echocardiography 
may play a role in the indication of abdominal surgery 
and postoperative management in the setting of LC. 
Cirrhotic cardiomyopathy may also be involved in the 
pathogenesis of hepatorenal syndrome (HRS) or the 
development of acute kidney injury (AKI). AKI can 
lead to a positive fluid balance, resulting in vital organ 
edema related to cardiac output performance[51,52]. LC 
may cause renal dysfunction and HRS; which occurs in 
conjunction with microcirculatory dysfunction in other 
organs, including the heart and the peripheral vascular 
bed[53]. Assessment of preoperative renal function is 
of paramount importance due to the high influence 
of AKI on postoperative survival in LC patients[54,55]. 
Thus, the identification of high creatinine levels as an 
independent predictor of complications and mortality in 
LC patients undergoing surgery was not surprising[56]. 
Ascites, respiratory dysfunction, and hyponatremia
Ascites and fluid overload may cause or aggravate 
pulmonary function due to atelectasis and pulmonary 
edema. In advanced LC, hepatopulmonary syndrome, 
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saline) may worsen ascites and peripheral edema and 
have little effect over intravascular volumes[65]. Indeed, 
intravascular volume may be depleted, even in the 
setting of extravascular volume overload[14]. Thus, it 
seems more appropriate to provide fluid support in the 
form of a volume expander if necessary, prioritizing 
fluid restriction. Blood products should be used 
routinely, and TEG can achieve optimal monitoring of 
coagulopathy. The increased physiological demand that 
surgery represents in patients with identified cirrhotic 
cardiomyopathy can lead to heart failure. Minimization 
of large fluctuations in preload and afterload are 
recommended in order to improve outcomes. The 
avoidance of heart failure during the perioperative 
period has important prognostic implications[66]. It 
is important to note that most of these patients are 
currently receiving treatment with β-blockers[67], which 
may ultimately reduce the cardiac response under 
stressful conditions. Thus, a closer monitoring of 
cardiac performance and the prompt use of inotropes 
and vasoconstrictors are mandatory in order to avoid 
low cardiac output and intraoperative hypotension. 
Perioperative antibiotic prophylaxis should be given 
in the presence of ascites to prevent postoperative 
SBP or bacteremia secondary to SBP, which may 
occur during the procedure. The most frequent micro-
biological causes, such as gram-negative bacteria, 
must be covered[68]. Although quinolones are the 
most frequently used antibiotic for SBP prophylaxis, 
an individualized approach is needed due to the 
emergence of multidrug-resistant agents[69]. 
Pain and sedative management regimens need to 
be minimized and adapted according to the degree 
of liver disease and the alterations to the metabolism 
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Table 1  Recommendations for evaluation before non-hepatic abdominal surgery in liver cirrhotic patients
Elements to evaluate Recommended tests Recommended action
Homeostasis Thrombo-cytopenia Platelet number and function by 
means of thromboelastography
Preoperative transfusion if:
Platelet > 50000/µL → moderate risk procedures
Platelet > 100000/µL → high risk procedures
Consider desmopressin (300 µg intranasal) if uremia or altered platelet function in 
thromboelastography
Coagulopathy PT-INR; thromboelastography. IV replenishment of vitamin K (≥ 10 mg OD during 3 d)
Serum fibrinogen; Cryoprecipitate if serum fibrinogen ≥ 100 mg/dL
Thromboelastography
Consider Tranexamic acid (10 mg/kg TD during 2-7 d)
Liver function PTH Abdominal US Consider the less invasive surgical treatment or avoid surgery if severe PTH
Consider TIPS
Ascites Diagnostic ascitic tap; check 
diuretics response
Discard SBP
Antibiotic prophylaxis or treatment.
Sodium restriction and diuretics (careful monitoring of renal function avoiding 
hyponatremia)
Large volume of paracentesis for uncontrolled ascites
Esophageal varices Upper endoscopy; Abdominal 
US












Optimize protein and caloric intake (higher requirements than normal individuals)
 Vitamin B1 in alcoholics
Administer antibiotic prophylaxis if suspected concurrent infections 
(Other than SBP)






Consider the less invasive surgical treatment or avoid surgery if severe cardiac 
dysfunction
Consider close invasive monitoring and hemodynamic  strategy in order to 
preserve normal cardiac function and avoid organ hypoperfusion 
(especially liver and kidney)
Consider β-blockers in perioperative period




Glomerular filtration rate; 
Evaluate normal Blood Pressure 
and cardiac performance
Avoid dehydration if possible before surgery
Avoid positive fluid balance during perioperative course 











Discard high arterial pulmonary pressure
Discard pleural effusion/thoracentesis if necessary
If HPS/PPH evaluate appropriate therapy (i.e., IV epoprostenol, sildenafil)
CNS HE Clinical assessment; Use of lactulose despite absence of HE if medical past history or PTH
Ammonia serum levels Treat or avoid potential triggers of HE (i.e., diuretics, infections, constipations, 
CNS depressants, azotemia, uremia, hyponatremia)
PT-INR: Prothrombin time-derived international normalized ratio; IV: Intravenous; PTH: Portal hypertension; US: Ultrasound; TIPS: Transjugular 
intrahepatic portosystemic shunt; SBP: Spontaneous bacterial peritonitis; HPS: Hepatopulmonary syndrome; PPH: Portopulmonary hypertension; CNS: 
Central nervous system; HE: Hepatic encephalopathy.
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caused by these anesthetic drugs. Portal blood flow is 
reduced as a result of PHT, and anesthetic agents may 
reduce hepatic blood flow by 30%-50% as a result 
of impaired autoregulation. In addition, myocardial 
depression and vasodilatation are frequent in most 
anesthetic agents[70]. Agents with minimal hepatic 
metabolism (< 0.2%), such as isoflurane, desflurane, 
and sevoflurane together with nitrous oxide, are an 
appropriate choice for the operating room, along with 
propofol as a narcotic agent[71,72]. These agents also 
cause fewer disturbances in hepatic arterial blood 
flow than others[73]. Atracurium and cisatracurium 
are preferred as muscle relaxants since they are 
metabolized independently from the liver;  vecuronium 
and rocuronium, on the other hand, are metabolized 
exclusively by the liver and must be avoided[74,75]. 
Some authors argue that epidural anesthesia should 
be avoided in LC patients due to the complications 
derived from the coagulopathy[8]. However, epidural 
analgesia has many benefits, not only in terms of pain 
control during and after surgery, but also in terms of 
reducing pulmonary, cardiovascular, thromboembolic, 
and gastrointestinal complications and enhancing the 
recovery of gut function after abdominal surgery[76]. 
In our opinion, epidural anesthesia may be safe in 
the absence of abnormal coagulation and/or platelet 
count, especially if evaluated preoperatively by means 
of TEG. 
Surgical considerations
Surgery should ideally be elective, due to the higher 
than average risk associated with emergency surgery 
in cirrhotic patients[1,7-11]. Careful tissue handling and 
meticulous surgical technique are vital to prevent 
major bleeding during surgery. Morbidity and mortality 
rates vary greatly depending on the severity of the 
cirrhosis, the presence of PHT, complications of LC, and 
the nature of the surgical procedure. 
The incidence of gall stones and hernia is higher 
in LC than in the non-cirrhotic population due to the 
increased intra-abdominal pressure. Cholecystectomy 
and hernia repair surgery are the most frequently 
described surgeries in LC, and modified laparoscopic 
techniques have been proposed in these cases in 
order to minimize morbidity (Table 2)[77-82]. The use of 
laparoscopy allows non-exposure of viscera and restricts 
electrolytic and protein losses[79]. From the technical 
point of view, the use of coagulation instruments like 
the harmonic scalpel causes less postoperative pain 
and lower morbidity[83,84]. The use of laparoscopic 
general surgery is also supported by the lower 
morbidity rates, lower bleeding complications, shorter 
operating time and hospital stay (despite the higher 
conversion rates to open surgery during the procedure, 
especially in the case of emergency surgery), and 
fewer bleeding-related complications compared to non-
cirrhotic patients[77,85,86]. The laparoscopic approach 
also helps to reduce morbidities such as surgical 
site infection and hemorrhage[87]. A wide range of 
interventions can be performed laparoscopically in 
LC patients: splenectomies, colectomies, Nissen 
fundoplication, Heller’s myotomy, gastric bypass, radical 
nephrectomy[88], appendectomies[89], suture closure, 
and placement of an omental patch for treatment of a 
perforated gastric ulcer[90].
Although, in general, outcomes are poorer in LC 
patients than in the non-LC population in terms of 
morbidity and mortality, mortality rates are quite 
similar in certain surgeries thanks to the technical 
advances and experience gained in recent years (Table 
3)[10,77-79,81-87,89,91-101]. One example is abdominal wall 
surgery. Elective repair of umbilical hernia in patients 
with LC and ascites is indicated due to the poor 
outcomes with conservative management[102-104]; and, 
even in advanced LC, inguinal hernia repair obtains 
similar outcomes to those recorded in the non-LC 
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Table 2  Modifications in operative laparoscopic techniques in non-hepatic abdominal surgery in liver cirrhosis who underwent 
cholecystectomy and hernia repair
Ref. Modified technique Objective and advantage
Laparoscopic cholecystectomy
Friel et al[77], 1999 Use of open technique using Hassan’s trocar Prevent inadvertent puncture of umbilical varix
Shiff et al[78], 2005 Placement of the trocar in the right paramedian position
Clark et al[79], 2001 Use of additional ports Facilitate laparoscopic technique and prevent 
complications in cases of severe gallbladder 
inflammation
Performance of retrograde cholecystectomy
Clark et al[79], 2001 Modified subtotal cholecystectomy
Palanivelu et al[80], 2006 
Friel et al[77], 1999 Mechanical compression from introduced surgical sponges 
(i.e., oxidized cellulose)
Facilitate haemostasis
Application of ultrasonic energy via harmonic scalpel
Use of argon beam coagulator through an operative port
Laparoscopic hernia repair
Belli et al[81], 2006 Minimally invasive and tension-free laparoscopic technique Prevent inadvertent puncture of collateral veins
Prevent recurrence rates and wound infections
McAlister et al[82], 2003 Dual mesh prosthesis: fixation of mesh in a preperitoneal space Prevent recurrence rates and mesh migration
Sterile fashion of mesh insertion Prevent wound infections
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population and improves quality of life[81,82,100-110].
POSTOPERATIVE MANAGEMENT
Postoperative management should ideally be 
performed in the ICU, at least during the first 24 
h, especially in CTP B and C. It is important to 
monitor for the complications that may be expected 
depending on the degree of LC and type of surgery. As 
discussed above, postoperative management should 
be based on the pathophysiological characteristics of 
LC. Physicians should focus on fluid management, 
vigilance, and prophylaxis of infections (especially 
surgical site infections); opioids and sedatives should 
be used cautiously. The inadequate administration 
of normal saline can lead to the development of 
ascites. Salt restriction with both intravenous fluid 
and oral intake is mandatory in order to prevent 
the postoperative occurrence of AKI, ascites, and/or 
hepatic encephalopathy[111,112]. Early introduction 
of lactulose should prevent encephalopathy. In the 
presence of fast decompensation of liver function, 
physicians should first rule out infection[113]. The 
dosage of analgesics for pain control should be based 
on the degree of liver dysfunction because the drug 
metabolism of simple analgesics, such as paracetamol, 
non-steroidal, and opioid analgesics, may be impaired. 
If opioids are necessary, fentanyl is preferred because 
it does not produce active metabolites; however, it 
may accumulate in the fat tissue for several days and 
is cleared through the liver[114].
CONCLUSION
Patients with LC undergoing non-hepatic abdominal 
surgery are at an increased risk of poor outcome. 
Emergency surgery should be avoided if possible, and 
conservative management is preferred in the presence of 
decompensated LC, alcoholic hepatitis, severe/advanced 
LC, and significant extrahepatic organ dysfunction. A 
multidisciplinary team approach involving surgeons, 
anesthesists, intensivists, and gastroenterologist/
hepatologists together with specialized hospital staff 
with experience in the perioperative management of 
those patients can improve outcomes. Since there are 
no formal guidelines and few randomized controlled 
trials have been performed, the pathophysiological 
characteristics of LC mean that an individualized 
approach to the care of the patients is essential. 
Preoperative optimization after risk stratification is 
mandatory before surgery. Laparoscopic techniques 
may improve outcomes in those patients, and recent 
advances in cholecystectomy, abdominal wall surgery, 
and appendectomy have reduced mortality to levels 
similar to those found in the non-LC population. Future 
prospective randomized studies are needed to assess 
the effect of preoperative TIPS, to compare elective 
surgery vs conservative management, and to compare 
preoperative assessment with MELD and CTP scores 
for specific surgical procedures. These studies should 
also assess the efficacy of new approaches, especially 
before surgery, in order to establish formal guidelines for 
the management of patients with LC undergoing non-
hepatic abdominal surgery.
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